# Statin-dye conjugates for selective targeting of KRAS mutant cancer cells

## TL;DR

Researchers developed statin-dye conjugates that selectively target cancer cells with KRAS mutations, showing promise for more effective pancreatic cancer treatment.

## Contribution

The novel use of statin-dye conjugates to selectively target and kill KRAS mutant cancer cells through enhanced macropinocytosis.

## Key findings

- Statin-Cy5.5 conjugates showed significantly higher uptake in KRAS mutant cells compared to wild-type cells.
- Pravastatin-Cy5.5 selectively killed KRAS mutant pancreatic cancer cells without harming associated fibroblasts.
- Enhanced uptake was also observed in PTEN-deficient cells, linking it to increased macropinocytosis.

## Abstract

Over 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve KRAS mutations (KRASMUT), for which current treatment options are limited. Statins, commonly used to lower cholesterol, have demonstrated certain selective toxicity towards KRAS-transformed cells, prompting the question of whether statin-based conjugates could achieve selective uptake specifically in KRASMUT cells. To investigate this, we synthesized statin-dye conjugates by attaching a fluorescent dye (Cy5.5) to two statins: simvastatin and pravastatin, aiming to assess whether selective uptake indeed occurs. Our findings revealed that these conjugates exhibited markedly enhanced uptake in KRASMUT cells compared to KRAS wild-type (KRASWT) cells. We evaluated the uptake of these conjugates in both KRASMUT and KRASWT cells and examined their potential to selectively target KRASMUT pancreatic cancer cells (PCCs) using an engineered PDAC tumor model co-cultured with PCCs and cancer-associated fibroblasts (CAFs). Our findings indicate that KRASMUT cancer cells exhibited higher uptake of statin-Cy5.5 conjugates via enhanced macropinocytosis compared to KRASWT cancer cells and CAFs. We also found enhanced uptake of the statin-Cy5.5 conjugate in MCF10A cells with PTEN deficiency, a condition known to elevate macropinocytosis, compared to control MCF10A cells with wild-type PTEN. Notably, in the PCC and CAF co-culture model, the pravastatin-Cy5.5 conjugate selectively killed KRASMUT PCCs without affecting the KRASWT CAFs. These findings highlight the unique synergistic potential of statin-Cy5.5—distinct from either component alone—as targeted delivery vehicles for KRASMUT cancer therapy.